Latest news with #VinceLamanna
Cision Canada
13-05-2025
- Health
- Cision Canada
Organizations can help make local history and win $100,000 for their community Français
ParticipACTION launches its country-wide Community Challenge in search of Canada's Most Active Community. TORONTO, May 13, 2025 /CNW/ - On June 1, ParticipACTION will kick off its search for Canada's Most Active Community with the ParticipACTION Community Challenge presented by Novo Nordisk. ParticipACTION encourages everyone in Canada to get physically active throughout June to help their community win the title and $100,000 grand prize to support local sport and physical activity initiatives. The Community Challenge is open to all communities, organizations and individuals. Community organizations, including sport clubs, community centres, local businesses and schools, as well as local governments, can now sign up for the Challenge and register the physical activity and sport programs and events they plan to run in June to help their community members get more active where they live, learn, work and play. All community programs and events registered on the Challenge webpage and hosted in June will count toward a community's total score. "There is no world record to break, but local history can be made throughout the Challenge," says Elio Antunes, President and CEO of ParticipACTION. "Through this community-focused initiative and the leadership of local organizations across the country, we're hoping to reduce barriers and create more fun and inclusive opportunities for people in Canada to get active. When it comes to making room to move during the Challenge, there are no set parameters – every cartwheel competition, soccer practice and neighbourhood walk or wheel counts!" Everyone in Canada should have access to quality sport and physical activity opportunities that help them grow and thrive – physically, emotionally and socially. ParticipACTION, with support from public and private funders, provided funding to more than 900 community organizations to promote and deliver physical activity and sport opportunities to equity-denied groups throughout the 2025 Challenge. This funding helps level the playing field and reduces barriers to physical activity, contributing to the creation of stronger, more inclusive and healthier communities. "At Novo Nordisk, we believe that a healthier Canada will take more than medication. As obesity and diabetes rates continue to rise and place greater burden on the economy, we must equally prioritize prevention. That's why we invest in prevention initiatives that make a real difference and why we're proud to partner on this year's ParticipACTION Community Challenge presented by Novo Nordisk," says Vince Lamanna, President, Novo Nordisk Canada. "Physical activity is essential for our physical and mental health, helping to prevent serious chronic diseases like obesity and diabetes. Through partnerships like this, we are committed to ensuring that wellness reaches more families and communities across Canada. Together, we can inspire action, cultivate healthier lifestyles and create lasting change for a healthier tomorrow." Past national winners of the ParticipACTION Community Challenge include Enderby, B.C. (2019), North Grenville, Ontario (2021), Red Deer, Alberta (2022), Salisbury, New Brunswick (2023) and Hay River, Northwest Territories (2024). In Hay River, the $100,000 prize is supporting upgrades to local sport and recreation programming and the revitalization of Inukshuk Park, helping to transform it into an active gathering place for community events, outdoor fitness and everyday movement. It's a lasting reminder that when a community makes room to move, it creates space for everyone to thrive. To learn more about how to participate in the Community Challenge and register your organization, visit ParticipACTION's website. About ParticipACTION ParticipACTION is a national non-profit charitable organization that envisions a Canada where physical activity is a vital part of everyday life for everyone. As Canada's leading physical activity organization, ParticipACTION works with its partners, which include organizations in the sport, physical activity and recreation sectors, alongside government and corporate sponsors, to help people move more where they live, learn, work and play. ParticipACTION is generously supported by the Government of Canada. Learn how ParticipACTION has been moving Canadians for over 50 years at The ParticipACTION Community Challenge presented by Novo Nordisk is a national physical activity and sport initiative that encourages everyone in Canada to get active throughout June in search of Canada's Most Active Community. The Community Challenge is open to all communities and individuals, ultimately recognizing Canada's Most Active Community and awarding it $100,000 to support local physical activity and sport initiatives. The ParticipACTION Community Challenge presented by Novo Nordisk is proudly funded by the Government of Canada and Novo Nordisk.
Yahoo
02-05-2025
- Health
- Yahoo
Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy
It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%.1 Left untreated, MASH can progress to serious and even fatal outcomes, such as cirrhosis, liver cancer, and the need for liver transplant.2 MISSISSAUGA, ON, May 2, 2025 /CNW/ - Today, Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once weekly therapy for people living with MASH (metabolic dysfunction-associated steatohepatitis). "Semaglutide 2.4 mg represents a therapeutic advancement for patients living with MASH, addressing a critical unmet medical need," says Vince Lamanna, President of Novo Nordisk Canada Inc. "Health Canada's acceptance of the Semaglutide 2.4 mg submission for review brings us one step closer to providing the first treatment option for eligible people living with MASH." About semaglutide 2.4 mgSemaglutide injection 2.4 mg is currently approved by Health Canada for chronic weight management and non-fatal myocardial infarction (MI) risk reduction in adults with established cardiovascular disease and BMI ≥ 27 kg/m2.3 Semaglutide is not approved in Canada for the treatment of MASH. Safety and efficacy are not established, and there is no guarantee that semaglutide will become commercially available for this use under clinical investigation. About Metabolic Dysfunction-Associated Steatohepatitis (MASH) MASH is a chronic, progressive metabolic disease affecting the liver, which can be potentially life-threatening if not properly managed.4,5 Among people who are living with overweight or obesity, approximately one in three also have MASH.6 Excess fat can build up in the liver, which, over time, can lead to inflammation and severe scarring of the liver.7 People living with MASH often experience few or no specific symptoms in the early stages of the disease, which often results in a delayed diagnosis.8 It is estimated that by 2030 the prevalence of MASH in the Canadian general population will increase from 5.2% to 6.5%.1 In Canada, the number of deaths are expected to double in people living with MASH by 2030.1 About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. _______________________________ 1 Swain M et al. CMAJ Open 2020;8:E429-E436. CMA open, 8(2), June 2020 2 Fichez J, Mouillot T, Vonghia L, et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials. JHEP Reports. 2025;7(4);101351. doi:10.1016/ 3 Novo Nordisk Canada Inc. (2025, April 8). Wegovy® Product Monograph. 4 Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol. 2018;31:296-304. doi:10.20524/aog.2018.0248 5 Tesfay M, Goldkamp JW, Neuschwander-Tetri BA. NASH: the emerging most common form of chronic liver disease. Mo Med. 2018;115:225-229 6 Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:20-30. doi: 10.1016/S2468-1253(22)00317-X 7 National Institute of Diabetes and Digestive and Kidney Diseases. Definition & facts of NAFLD & NASH. Accessed November 7, 2024. Available at: 8 Allen AM, Charlton M, Cusi K, et al. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024;136:229-245. doi:10.1080/00325481.2024.2325332 SOURCE Novo Nordisk Canada Inc. View original content to download multimedia: Sign in to access your portfolio
Cision Canada
02-05-2025
- Health
- Cision Canada
Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy
It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%. 1 Left untreated, MASH can progress to serious and even fatal outcomes, such as cirrhosis, liver cancer, and the need for liver transplant. 2 MISSISSAUGA, ON, May 2, 2025 /CNW/ - Today, Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once weekly therapy for people living with MASH (metabolic dysfunction-associated steatohepatitis). "Semaglutide 2.4 mg represents a therapeutic advancement for patients living with MASH, addressing a critical unmet medical need," says Vince Lamanna, President of Novo Nordisk Canada Inc. "Health Canada's acceptance of the Semaglutide 2.4 mg submission for review brings us one step closer to providing the first treatment option for eligible people living with MASH." About semaglutide 2.4 mg Semaglutide injection 2.4 mg is currently approved by Health Canada for chronic weight management and non-fatal myocardial infarction (MI) risk reduction in adults with established cardiovascular disease and BMI ≥ 27 kg/m 2. 3 Semaglutide is not approved in Canada for the treatment of MASH. Safety and efficacy are not established, and there is no guarantee that semaglutide will become commercially available for this use under clinical investigation. About Metabolic Dysfunction-Associated Steatohepatitis (MASH) MASH is a chronic, progressive metabolic disease affecting the liver, which can be potentially life-threatening if not properly managed. 4, 5 Among people who are living with overweight or obesity, approximately one in three also have MASH. 6 Excess fat can build up in the liver, which, over time, can lead to inflammation and severe scarring of the liver. 7 People living with MASH often experience few or no specific symptoms in the early stages of the disease, which often results in a delayed diagnosis. 8 It is estimated that by 2030 the prevalence of MASH in the Canadian general population will increase from 5.2% to 6.5%. 1 In Canada, the number of deaths are expected to double in people living with MASH by 2030. 1 About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. SOURCE Novo Nordisk Canada Inc.
